Hiroki Hosoi

A Case of Leukemic Phase of Mantle Cell Lymphoma Diagnosed With Scarring Conjunctivitis and Bilateral Upper Palpebral Conjunctival Tumor

Takayoshi Sumioka, Shingo Yasuda, Kazuki Imai, Hiroki Iwanishi et autres

Purpose: Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin's lymphoma. Ocular adnexal involvement is rare as the initial symptom, and conjunctival involvement is particularly rare. Methods: An 84-year-old man was referred to our hospital with chronic conjunctivitis of the bulbar and …

jp (code pays fourni par la source)

Optimizing cord blood unit selection to improve survival after single‐unit unrelated cord blood transplantation for adult myelodysplastic syndrome

Takaaki Konuma, Machiko Fujioka, Kyoko Fuse, Tatsuya Suwabe et autres

Summary Unrelated cord blood transplantation (CBT) is an important alternative donor option for adult patients with myelodysplastic syndrome (MDS); however, the prognostic significance of cord blood unit characteristics following CBT remains unclear and may vary according to disease risk. We conducted a …

jp (code pays fourni par la source)

Prognostic factors of second allogeneic hematopoietic stem cell transplantation for relapsed or refractory myelodysplastic syndromes: nationwide registry analysis

Kamma Shiraishi, Yoshimitsu Shimomura, Hiroki Hosoi, Kyoko Fuse et autres

jp (code pays fourni par la source)

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3 ‐ ITD –Positive AML

Yuichiro Semba, Toshihiro Miyamoto, Senji Kasahara, Yoshikane Kikushige et autres

Quizartinib is a FMS-like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3-ITD-positive AML. …

jp (code pays fourni par la source)

Bidirectional associations between bacteraemia and cytomegalovirus infection after allogeneic haematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy Transplant Complications Working Group

Shun-ichi Kimura, Kazuki Yoshimura, Hideki Nakasone, Hiroki Hosoi et autres

jp (code pays fourni par la source)

GUIDELINE FOR THE USE OF PLATELET TRANSFUSION CONCENTRATES BASED ON SCIENTIFIC EVIDENCE: UPDATE 2025

Akiyoshi Takami, Masao Ogata, Yoshiaki Tomiyama, Nobuharu Fujii et autres

【ガイドライン】 Guideline 科学的根拠に基づいた血小板製剤の使用ガイドライン：2025 年改訂版高見 昭良 1) 11) 緒方 正男 2) 11) 冨山 佳昭 3) 11) 藤井 伸治 4) 11) 久冨木庸子 5) 11) 藤原慎一郎 6) 11) 細井 裕樹 7) 11) 小川 孔幸 8) 11) 松本 雅則 9) 10) キーワード：がん・造血器悪性腫瘍，造血不全，外科手術，活動性出血，超低体重児 推奨一覧 CQ1 固形腫瘍，造血器悪性腫瘍，自家・同種造血幹細胞移植における血小板輸血はどのように行うべきか 固形腫瘍における血小板輸血トリガー値は …

jp, us (code pays fourni par la source)

科学的根拠に基づいた血小板製剤の使用ガイドライン：2025年改訂版

Akiyoshi Takami, Masao Ogata, Yoshiaki Tomiyama, Nobuharu Fujii et autres

jp (code pays fourni par la source)

Distribution of CD30-positive tumor cell proportions in adult T-cell leukemia/lymphoma

Kikuaki Yoshida, Toshiki Mushino, Ken Tanaka, Hideki Kosako et autres

Adult T-cell leukemia/lymphoma (ATLL) is a refractory mature T-cell malignancy that is etiologically associated with human T-cell leukemia virus type 1. It is endemic in several regions, including ...

jp (code pays fourni par la source)

Detection of BRAF V600E on the Re-evaluation in Erdheim-Chester Disease with Prior Negative Testing

Hiroki Hosoi, Ikuro Tanigawa, Takashi Nouchi, Makiko Sogabe et autres

jp (code pays fourni par la source)

Letermovir prophylaxis and risk of bacterial or fungal infection after allogeneic hematopoietic cell transplantation

Shun‐ichi Kimura, Shunto Kawamura, Takashi Toya, Keiji Okinaka et autres

jp (code pays fourni par la source)

Severe and/or prolonged COVID-19 in hematologic diseases: clinical implications before and during the omicron era

Akinao Okamoto, Masahiro Yoshida, Senji Kasahara, Takahide Ara et autres

Background Although the Omicron variant has been reported to reduce COVID-19 severity in the general population, its impact on patients with hematologic malignancies remains uncertain, and epidemiological investigation is warranted. Methods We conducted a multicenter retrospective cohort study of 1, 023 patients …

jp, us (code pays fourni par la source)

Outcomes of second hematopoietic stem cell transplantation for relapsed myelodysplastic syndrome: An updated analysis of Japanese nationwide transplant registry

Kamma Shiraishi, Yoshimitsu Shimomura, Hiroki Hosoi, Kyoko Fuse et autres

Abstract Background Myelodysplastic syndrome (MDS) is associated with dismal outcomes after relapse following hematopoietic stem cell transplantation (HSCT), a situation that remains a clinical challenge. The median overall survival (OS) for patients who relapsed after HSCT has been reported to be only …

jp (code pays fourni par la source)